 |
|
|
|
|
|
 |
 |
| |
|
Section I
Table S1. Pediatric AML
sample characteristics
|
Case
identifier
|
subtypea
|
MLL statusb
|
FABc
|
Sampled
|
% Blastse
|
Protocolf
|
|
inv16-#01
|
CBFb-MYH11
|
|
M4E
|
BM
|
94
|
AML83
|
|
inv16-#02
|
CBFb-MYH11
|
|
M4
|
BM
|
98
|
AML87
|
|
inv16-#03
|
CBFb-MYH11
|
|
M4E
|
BM
|
89
|
AML87
|
|
inv16-#04
|
CBFb-MYH11
|
|
M4
|
BM
|
80
|
AML91
|
|
inv16-#05
|
CBFb-MYH11
|
|
M4E
|
BM
|
85
|
AML91
|
|
inv16-#06
|
CBFb-MYH11
|
|
M4
|
BM
|
77
|
AML91
|
|
inv16-#07
|
CBFb-MYH11
|
|
M4E
|
BM
|
85
|
AML97
|
|
inv16-#08
|
CBFb-MYH11
|
|
M4E
|
BM
|
88
|
AML97
|
|
inv16-#09
|
CBFb-MYH11
|
|
M4E
|
BM
|
89
|
AML87
|
|
inv16-#10
|
CBFb-MYH11
|
|
M4E
|
BM
|
79
|
AML97
|
|
inv16-#11
|
CBFb-MYH11
|
|
M1
|
BM
|
88
|
AML97
|
|
inv16-#12
|
CBFb-MYH11
|
|
M4E
|
BM
|
86
|
AML97
|
|
inv16-#13
|
CBFb-MYH11
|
|
M1E
|
BM
|
96
|
AML83
|
|
inv16-#14
|
CBFb-MYH11
|
|
M4E
|
BM
|
66
|
non
protocol
|
|
MLL-#01
|
MLL
|
t(11;19)
|
M4
|
BM
|
91
|
AML87
|
|
MLL-#02
|
MLL
|
t(9;11)
|
M5a
|
BM
|
73
|
AML87
|
|
MLL-#03
|
MLL
|
t(6;11)
|
M5b
|
BM
|
96
|
AML91
|
|
MLL-#04
|
MLL
|
t(3;11)
|
M5a
|
BM
|
94
|
AML91
|
|
MLL-#05
|
MLL
|
t(1;11)
|
M5a
|
PB
|
88
|
AML91
|
|
MLL-#06
|
MLL
|
t(10;11)
|
M5a
|
BM
|
77
|
AML91
|
|
MLL-#07
|
MLL
|
t(9;11)
|
M5a
|
BM
|
96
|
AML91
|
|
MLL-#08
|
MLL
|
t(9;11)
|
M5a
|
BM
|
88
|
AML91
|
|
MLL-#09
|
MLL
|
t(7;9;11)
|
M5a
|
BM
|
92
|
AML91
|
|
MLL-#10
|
MLL
|
t(9;11)
|
M5a
|
BM
|
80
|
AML91
|
|
MLL-#11
|
MLL
|
t(11;19)
|
M5b
|
PB
|
90
|
AML91
|
|
MLL-#12
|
MLL
|
t(9;11)
|
M5a
|
BM
|
87
|
AML91
|
|
MLL-#13
|
MLL
|
t(1;11)
|
M5a
|
BM
|
98
|
AML91
|
|
MLL-#14
|
MLL
|
t(11;19)
|
M1
|
BM
|
95
|
AML97
|
|
MLL-#15
|
MLL
|
t(1;11)
|
M5a
|
BM
|
90
|
AML97
|
|
MLL-#16
|
MLL
|
t(10;11)
|
M5a
|
apheresis
|
97
|
AML97
|
|
MLL-#17
|
MLL
|
t(9;11)
|
M5a
|
BM
|
97
|
AML97
|
|
MLL-#18
|
MLL
|
t(9;11)
|
M1
|
BM
|
96
|
AML97
|
|
MLL-#19
|
MLL
|
t(10;11)
|
M5a
|
BM
|
70
|
AML97
|
|
MLL-#20
|
MLL
|
t(11;16)
|
M5b
|
BM
|
88
|
AML91
|
|
MLL-#21
|
MLL
|
t(9;11)
|
M5a
|
BM
|
96
|
AML87
|
|
MLL-#22
|
MLL
|
t(4;11)
|
M5a
|
PB
|
97
|
AML97
|
|
MLL-#23
|
MLL
|
t(10;11)
|
M5a
|
PB
|
71
|
AML97
|
|
t(15:17)-#01
|
PML-RARa
|
|
M3
|
BM
|
95
|
AML87
|
|
t(15:17)-#02
|
PML-RARa
|
|
M3
|
PB
|
88
|
AML83
|
|
t(15:17)-#03
|
PML-RARa
|
|
M3
|
BM
|
89
|
PG9220
|
|
t(15:17)-#04
|
PML-RARa
|
|
M3
|
BM
|
83
|
non
protocol
|
|
t(15:17)-#05
|
PML-RARa
|
|
M3
|
BM
|
95
|
non
protocol
|
|
t(15:17)-#06
|
PML-RARa
|
|
M3
|
BM
|
88
|
PG9710
|
|
t(15:17)-#07
|
PML-RARa
|
|
M3
|
PB
|
87
|
El-Salvador
|
|
t(15:17)-#08
|
PML-RARa
|
|
M3
|
BM
|
91
|
El-Salvador
|
|
t(15:17)-#09
|
PML-RARa
|
|
M3
|
BM
|
97
|
El-Salvador
|
|
t(15:17)-#10
|
PML-RARa
|
|
M3
|
BM
|
87
|
non
protocol
|
|
t(15:17)-#11
|
PML-RARa
|
|
M3
|
BM
|
94
|
PG9710
|
|
t(15:17)-#12
|
PML-RARa
|
|
M3
|
BM
|
90
|
PG9710
|
|
t(15:17)-#13
|
PML-RARa
|
|
M3
|
BM
|
93
|
non
protocol
|
|
t(15:17)-#14
|
PML-RARa
|
|
M3
|
BM
|
92
|
non
protocol
|
|
t(15:17)-#15
|
PML-RARa
|
|
M3
|
BM
|
93
|
AML87
|
|
t(8:21)-#01
|
AML1-ETO
|
|
M2
|
BM
|
74
|
AML87
|
|
t(8:21)-#02
|
AML1-ETO
|
|
M4E
|
BM
|
91
|
AML87
|
|
t(8:21)-#03
|
AML1-ETO
|
|
M2
|
BM
|
81
|
AML87
|
|
t(8:21)-#04
|
AML1-ETO
|
|
M2
|
BM
|
72
|
AML87
|
|
t(8:21)-#05
|
AML1-ETO
|
|
M2
|
BM
|
88
|
AML87
|
|
t(8:21)-#06
|
AML1-ETO
|
|
M2
|
BM
|
76
|
AML91
|
|
t(8:21)-#07
|
AML1-ETO
|
|
M2
|
BM
|
83
|
AML97
|
|
t(8:21)-#08
|
AML1-ETO
|
|
M2
|
BM
|
92
|
AML97
|
|
t(8:21)-#09
|
AML1-ETO
|
|
M2
|
BM
|
93
|
AML97
|
|
t(8:21)-#10
|
AML1-ETO
|
|
M2
|
BM
|
92
|
AML97
|
|
t(8:21)-#11
|
AML1-ETO
|
|
M2
|
BM
|
90
|
AML97
|
|
t(8:21)-#12
|
AML1-ETO
|
|
M2
|
BM
|
90
|
AML97
|
|
t(8:21)-#13
|
AML1-ETO
|
|
M2
|
BM
|
79
|
El-Salvador
|
|
t(8:21)-#14
|
AML1-ETO
|
|
M2
|
BM
|
95
|
El-Salvador
|
|
t(8:21)-#15
|
AML1-ETO
|
|
M2
|
BM
|
90
|
El-Salvador
|
|
t(8:21)-#16
|
AML1-ETO
|
|
M1
|
BM
|
92
|
El-Salvador
|
|
t(8:21)-#17
|
AML1-ETO
|
|
M2E
|
BM
|
80
|
El-Salvador
|
|
t(8:21)-#18
|
AML1-ETO
|
|
M1
|
BM
|
91
|
AML97
|
|
t(8:21)-#19
|
AML1-ETO
|
|
M2
|
BM
|
89
|
AML97
|
|
t(8:21)-#20
|
AML1-ETO
|
|
M2E
|
PB
|
99
|
AML87
|
|
t(8:21)-#21
|
AML1-ETO
|
|
M2
|
BM
|
76
|
non
protocol
|
|
Other-#01
|
Other
|
|
M1
|
BM
|
93
|
AML87
|
|
Other-#02
|
Other
|
|
M2
|
BM
|
98
|
AML87
|
|
Other-#03
|
Other
|
MLL-PTD
|
M1
|
BM
|
93
|
AML87
|
|
Other-#04
|
Other
|
|
M4E
|
BM
|
80
|
AML80
|
|
Other-#05
|
Other
|
|
M1
|
BM
|
93
|
AML87
|
|
Other-#06
|
Other
|
|
M1
|
BM
|
88
|
AML87
|
|
Other-#07
|
Other
|
MLL-PTD
|
M2
|
PB
|
84
|
AML87
|
|
Other-#08
|
Other
|
MLL-PTD
|
M2
|
BM
|
92
|
AML87
|
|
Other-#09
|
Other
|
MLL-PTD
|
M2
|
BM
|
81
|
AML87
|
|
Other-#10
|
Other
|
|
M2
|
BM
|
93
|
AML84
|
|
Other-#11
|
Other
|
|
M1
|
BM
|
95
|
AML87
|
|
Other-#12
|
Other
|
|
M2
|
BM
|
85
|
AML87
|
|
Other-#13
|
Other
|
MLL-PTD
|
M2
|
BM
|
83
|
AML91
|
|
Other-#14
|
Other
|
|
M1
|
BM
|
93
|
AML91
|
|
Other-#15
|
Other
|
MLL-PTD
|
M2
|
BM
|
75
|
AML91
|
|
Other-#16
|
Other
|
MLL-PTD
|
M1
|
BM
|
85
|
AML91
|
|
Other-#17
|
Other
|
|
M1
|
BM
|
89
|
AML91
|
|
Other-#18
|
Other
|
|
M4
|
BM
|
93
|
AML97
|
|
Other-#19
|
Other
|
|
M2
|
BM
|
94
|
AML91
|
|
Other-#20
|
Other
|
MLL-PTD
|
M1
|
BM
|
96
|
AML91
|
|
Other-#21
|
Other
|
|
M1
|
BM
|
84
|
AML91
|
|
Other-#22
|
Other
|
MLL-PTD
|
M2
|
BM
|
78
|
AML91
|
|
Other-#23
|
Other
|
|
M1
|
BM
|
95
|
AML97
|
|
Other-#24
|
Other
|
|
M4E
|
BM
|
85
|
AML97
|
|
Other-#25
|
Other
|
|
M1
|
BM
|
87
|
AML97
|
|
Other-#26
|
Other
|
MLL-PTD
|
M4
|
BM
|
93
|
AML97
|
|
Other-#27
|
Other
|
|
M1
|
BM
|
92
|
AML97
|
|
Other-#28
|
Other
|
|
M1
|
BM
|
98
|
AML97
|
|
Other-#29
|
Other
|
|
M1
|
BM
|
74
|
AML97
|
|
Other-#30
|
Other
|
|
M2
|
BM
|
86
|
AML97
|
|
Other-#31
|
Other
|
|
M1
|
BM
|
80
|
AML97
|
|
Other-#32
|
Other
|
|
M2
|
BM
|
78
|
AML97
|
|
Other-#33
|
Other
|
MLL-PTD
|
M5a
|
BM
|
92
|
AML87
|
|
Other-#34
|
Other
|
|
M5a
|
BM
|
93
|
AML87
|
|
Other-#35
|
Other
|
|
M4
|
BM
|
82
|
AML91
|
|
Other-#36
|
Other
|
|
M5a
|
BM
|
72
|
AML97
|
|
Other-#37
|
Other
|
|
M1
|
BM
|
95
|
AML97
|
|
Other-#38
|
Other
|
|
M1
|
BM
|
92
|
AML97
|
|
Other-#39
|
Other
|
|
M5a
|
BM
|
90
|
AML97
|
|
Other-#40
|
Other
|
|
M5a
|
BM
|
76
|
AML97
|
|
Other-#41
|
Other
|
|
M1
|
BM
|
89
|
AML97
|
|
Other-#42
|
Other
|
MLL-PTD
|
M2
|
BM
|
85
|
AML97
|
|
Other-#43
|
Other
|
MLL-PTD
|
M4
|
BM
|
80
|
AML97
|
|
Other-#44
|
Other
|
|
M4
|
BM
|
81
|
AML91
|
|
Other-#45
|
Other
|
|
M2
|
BM
|
77
|
AML91
|
|
Other-#46
|
Other
|
|
M1
|
BM
|
92
|
AML83
|
|
Other-#47
|
Other
|
|
M2
|
PB
|
95
|
AML83
|
|
Other-M7-#01
|
FAB-M7
|
|
M7
|
BM
|
82
|
AML87
|
|
Other-M7-#02
|
FAB-M7
|
|
M7
|
BM
|
78
|
AML87
|
|
Other-M7-#03
|
FAB-M7
|
|
M7
|
BM
|
78
|
non
protocol
|
|
Other-M7-#04
|
FAB-M7
|
|
M7
|
BM
|
50
|
AML97
|
|
Other-M7-#05
|
FAB-M7
|
|
M7
|
BM
|
80
|
AML97
|
|
Other-M7-#06
|
FAB-M7
|
|
M7
|
BM
|
68
|
AML97
|
|
Other-M7-#07
|
FAB-M7
|
|
M7
|
BM
|
90
|
AML91
|
|
Other-M7-#08
|
FAB-M7
|
|
M7
|
PB
|
73
|
AML91
|
|
Other-M7-#09
|
FAB-M7
|
|
M7
|
BM
|
97
|
non
protocol
|
|
Other-M7-#10
|
FAB-M7
|
|
M0*
|
BM
|
80
|
AML83
|
a AML subtype cases
were assigned to for this analysis. Translocation
was determined by at least two methods: cytogenetics,
FISH, and/or RT-PCR.
b MLL status: MLL-PTD
is partial tandem duplication, or translocation
partner is indicated for reciprocal translocations.
c French-American British type
as reviewed by M.Onciu. No examples of FAB-M3
variant were included.
d type of specimen evaluated:
BM = bone marrow; PB = peripheral blood.
e Percent blast in diagnostic
specimen post-ficoll purification.
f treatment protocols: AML83,
AML87, AML91, AML97 are St. Jude Chilren’s
Research Hospital institutional protocols. PG9710
Pediatric Oncology Cooperative Group study. El
Salvador refers to
patients treat in El
Salvador through SJCRH’s
Intrnational Outreach Program.
* morphologically and cytochemically this case was suggestive
of FAB-M7. CD41 was negative but no other megakaryocytic
markers were evaluated. This case was treated as FAB-M7
for purposes of these analyses.
|
|
|
|
|
| |
|
|
